9 Toxicity analysis of a multicenter study of adjuvant treatment with cyclophosphamide, adriamycin and 5-fluorouracil plus or minus high dose medroxyprogesteronacbtate (MPA) in early breast cancer

Journal of Steroid Biochemistry ◽

10.1016/0022-4731(87)91653-0 ◽

1987 ◽

Vol 28 ◽

pp. 203

Author(s):

J. Wils ◽

G.H. Blijham ◽

L. Scheuten

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Multicenter Study ◽

High Dose ◽

Toxicity Analysis

Download Full-text

An Open-label, Randomized Study Comparing 3 Years Tamoxifen Versus 3 Years Letrozole as Continuation of Adjuvant Treatment of Postmenopausal Women with Estrogen Receptor (ER) Positive and/or Progesterone Receptor (PR) Positive Early Breast Cancer Who Already Completed 2 years Adjuvant Tamoxifen. A Large Thai Multicenter Study.

http://isrctn.org/> ◽

10.1186/isrctn05585365 ◽

2012 ◽

Author(s):

Prasert Lertsaguansinchai

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Progesterone Receptor ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Multicenter Study ◽

Randomized Study ◽

Open Label ◽

Er Positive

Download Full-text

Adjuvant Treatment with High Dose Medroxyprogesterone Acetate in Node-Negative Early Breast Cancer A 3-year Interim Report on a Randomized Trial (I)

Acta Oncologica ◽

10.3109/02841868909111254 ◽

1989 ◽

Vol 28 (2) ◽

pp. 237-240 ◽

Cited By ~ 5

Author(s):

C. Focan ◽

A. Baudoux ◽

M. Beauduin ◽

U. Bunescu ◽

N. Dehasque ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Medroxyprogesterone Acetate ◽

High Dose ◽

Interim Report ◽

Node Negative

Download Full-text

Faculty Opinions recommendation of Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738708663.793581156 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

High Risk ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Node Positive

Download Full-text

Adjuvant treatment of early breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80272-1 ◽

2005 ◽

Vol 3 (3) ◽

pp. 149-166 ◽

Cited By ~ 1

Author(s):

Lissandra Dal Lago ◽

Chantal Bernard-Marty ◽

Martine J. Piccart

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment

Download Full-text

S31 Continuous infusional chemotherapy as pre-operative and as adjuvant treatment in early breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(97)89204-0 ◽

1998 ◽

Vol 34 ◽

pp. S8

Author(s):

I.E. Smith

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment

Download Full-text

High-Dose Medroxyprogesterone Acetate as Adjuvant Hormonotherapy in Early Breast Cancer: 9 Years Results of a Multicenter Randomized Trial

Contributions to Oncology - Hormone-Dependent Tumors ◽

10.1159/000424683 ◽

1995 ◽

pp. 145-158

Author(s):

C. Focan ◽

M. Beauduin ◽

E. Salamon ◽

J. De Greve ◽

G. De Wasch ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Early Breast Cancer ◽

Medroxyprogesterone Acetate ◽

High Dose ◽

Multicenter Randomized Trial

Download Full-text

The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer

memo - Magazine of European Medical Oncology ◽

10.1007/s12254-018-0448-3 ◽

2018 ◽

Vol 11 (4) ◽

pp. 272-275

Author(s):

Clemens Dormann ◽

Karl J. Aichberger

Keyword(s):

Breast Cancer ◽

Annual Meeting ◽

Early Breast Cancer ◽

Adjuvant Treatment

Download Full-text

Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer†

BioDrugs ◽

10.2165/11204680-000000000-00000 ◽

2010 ◽

Vol 24 (3) ◽

pp. 207-209 ◽

Cited By ~ 2

Author(s):

Karly P. Garnock-Jones ◽

Gillian M. Keating ◽

Lesley J. Scott

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Growth Factor Receptor ◽

Her2 Positive ◽

Human Epidermal Growth Factor ◽

Epidermal Growth

Download Full-text

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

European Journal of Cancer ◽

10.1016/j.ejca.2018.01.072 ◽

2018 ◽

Vol 93 ◽

pp. 19-27 ◽

Cited By ~ 29

Author(s):

X. Pivot ◽

I. Bondarenko ◽

Z. Nowecki ◽

M. Dvorkin ◽

E. Trishkina ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Reference Product ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

Download Full-text

CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

Value in Health ◽

10.1016/j.jval.2019.09.048 ◽

2019 ◽

Vol 22 ◽

pp. S405-S406

Author(s):

X. Guan ◽

H. Li ◽

Q. Chen ◽

C. Hao ◽

J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

High Risk ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Cost Effectiveness Analysis ◽

Her2 Positive ◽

Risk Of Recurrence ◽

Effectiveness Analysis

Download Full-text